Three separate investigations published in the past week have painted the same picture: retatrutide - an obesity drug that hasn’t been approved by any regulator in the world - is being sold openly through online vendors, social media, and apparently even at a Brooklyn bodega.
The Washington Post published an investigation on 2 July titled “Stronger than Ozempic. Not exactly legal. ‘Reta’ has entered the chat,” detailing how people are obtaining injectable retatrutide through underground supply chains. CBS News followed with their own piece about finding the compound for sale at a local shop in Brooklyn. And blockchain analytics firm Chainalysis reported that the grey market for peptides - including retatrutide - now exceeds $100 million USD annually, driven largely by cryptocurrency transactions.
What Is Retatrutide Again?
If you missed our earlier coverage, retatrutide is Eli Lilly’s triple-agonist drug that targets GLP-1, GIP, and glucagon receptors simultaneously. At the ADA 2026 conference, new data confirmed it achieves around 28.3% average body weight loss in clinical trials - outperforming every existing GLP-1 drug on the market.
Lilly is still running Phase 3 trials (the Triumph programme) and has not submitted for FDA approval yet. A regulatory filing is expected later in 2026 or early 2027. Yet somehow, vials of what people claim is retatrutide are circulating widely.
What the Investigations Found
Washington Post
The Post’s piece profiled people who had sourced “Reta” from online peptide vendors. One person described purchasing vials for a fraction of what compounded semaglutide costs, though the actual contents and purity of those vials are unknown. The article noted that some people are using retatrutide specifically because it is perceived as stronger than existing approved drugs.
CBS News
CBS reporters found what appeared to be retatrutide for sale at a physical retail location in Brooklyn, New York. The compound was not displayed on shelves - it was available through a “back room” arrangement. CBS tested samples and noted that without independent verification, there was no way to confirm whether the vials actually contained retatrutide, a different peptide, or something else entirely.
Chainalysis
The blockchain investigation firm reported that cryptocurrency payments for grey-market peptides have surged. Chainalysis tracked transactions across multiple darknet and clearnet platforms, finding that retatrutide was among the most frequently traded compounds alongside semaglutide, tirzepatide, and BPC-157.
What the Research Says
The clinical data for retatrutide is genuinely impressive. The Phase 2 data published in the New England Journal of Medicine showed dose-dependent weight loss up to 24.2% at 48 weeks. The Phase 3 Triumph programme has reported averages closer to 28.3%. These numbers are real, and they are why demand has outpaced the regulatory process.
But “impressive in clinical trials” and “safe to buy from a bodega” are not the same thing. In clinical settings, retatrutide is administered at precise doses with medical monitoring. The most common adverse events in trials were gastrointestinal (nausea, diarrhoea, vomiting). The dose escalation schedule exists for a reason.
We covered the Victoria health alert in June, where six Melbourne patients were hospitalised with acute liver toxicity after using products labelled as retatrutide. Those products were later found to be counterfeit or contaminated.
The Demand Problem
The existence of a $100 million grey market tells you something about the gap between what regulatory systems provide and what people want. Retatrutide delivers weight loss numbers that approach bariatric surgery. No approved drug currently matches it. People who have tried semaglutide or tirzepatide and plateaued see retatrutide as the next step - and when the only options are “wait 18 months for approval” or “buy it online right now,” a predictable number will choose the latter.
This isn’t an endorsement. It’s a description of a market dynamic that researchers, regulators, and harm-reduction advocates need to understand.
The Counterfeit Problem
The biggest risk in this space isn’t legal - it’s physical. When someone purchases “retatrutide” from an unregulated source, there is no guarantee about what’s in the vial. Possibilities include:
- Underdosed or overdosed retatrutide
- A different peptide entirely (semaglutide, tirzepatide, or something else)
- Contaminated or degraded compounds
- No active ingredient at all
Without independent analytical testing (HPLC, mass spectrometry), there is no way to verify what a grey-market vial contains. And the people most likely to purchase from these sources are the least likely to have access to testing.
Australian Context
The Australian Border Force has intercepted increasing volumes of peptide imports over the past two years. Retatrutide is not listed on the Australian Register of Therapeutic Goods and cannot legally be imported for personal use. The TGA’s position on unapproved peptides has been steadily tightening, with enforcement actions targeting both domestic sellers and importers.
For the Australian research community, the underground market represents both a risk and an information signal. The demand for next-generation compounds is real. The question is whether regulatory frameworks can move fast enough to provide safe, legitimate access before people turn to channels that offer no quality assurance.
Sources
Source: Washington Post - Stronger than Ozempic. Not exactly legal. ‘Reta’ has entered the chat - published July 2, 2026 Source: CBS News - What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug - published July 2, 2026 Source: Becker’s Hospital Review - The $100M ‘gray market’ of peptides: 5 notes - published July 7, 2026 Source: The Mail & Guardian - Illegal weight loss drug floods SA - published July 2, 2026 Source: Grey Highway - ADA 2026 Obesity Drug Showdown - published June 11, 2026
This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.